sintilimab,IBI939
innovent biologics,eli lilly
['sintilimab', 'nsclc', 'sclc', 'innovent']
innovent updates phase 1b data of ibi939 (anti- #tigit mab) +sintilimab in previously untreated pd-l1-selected nsclc at #asco23 rct in (small) n=42 2:1 (28/14)
mpfs per inv. 13.2mo - 95%ci=[6.7-16.5mo] vs 6.4mo [1.4-na] or hr 0.62 [mega wide ci expected] 
Biotellytics / https://t.co/37itIfRolp = business intel service on listed European Bios / Views=mine only, RT-like=/=endorse, no advice. 16y in Tech (chip design)